<DOC>
	<DOCNO>NCT01335997</DOCNO>
	<brief_summary>This study do find tablet contain extended release ( ER ) niacin , laropiprant , simvastatin ( ERN/LRPT/SIM ) effective tablet contain ER niacin laropiprant take simvastatin tablet ( ERN/LRPT + SIM ) lower high cholesterol high lipid level blood . The primary hypothesis ERN/LRPT/SIM 2 g /20 mg equivalent ERN/LRPT 2 g coadministered simvastatin 20 mg reduce low-density lipoprotein cholestrol ( LDL-C ) .</brief_summary>
	<brief_title>Efficacy Safety Extended-Release Niacin/ Laropiprant/Simvastatin Tablets Participants With Hypercholesterolemia Mixed Dyslipidemia ( MK-0524B-143 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Inclusion criterion : Has history primary hypercholesterolemia mixed dyslipidemia meet LDLC triglyceride criterion . Is high risk coronary heart disease ( CHD ) LDLC ≤190 mg/dL ( ≤4.91 mmol/L ) . Is high risk CHD LDLC ≤240 mg/dL ( ≤6.21 mmol/L ) . Exclusion criterion : Is pregnant breastfeeding , expect conceive donate egg sperm study . Has history malignancy within ≤5 year , except adequately treat basal cell squamous cell skin cancer situ cervical cancer . Consumes 3 alcoholic drink per day ( 14 per week ) . Is high risk CHD patient lipid modify therapy ( LMT ) . Is LMT equivalent great LDLClowering efficacy simvastatin 40 mg. Has Type 1 Type 2 diabetes mellitus poorly control , statin therapy . Currently engage vigorous exercise aggressive diet regimen . Has uncontrolled endocrine metabolic disease , uncontrolled gout , kidney hepatic disease , heart failure , recent peptic ulcer disease , hypersensitivity allergic reaction niacin simvastatin , recent heart attack , stroke heart surgery . Is human immunodeficiency virus ( HIV ) positive . Has take niacin &gt; 50 mg/day , bileacid sequestrants , 3hydroxy3methylglutarylcoenzyme A ( HMGCoA ) reductase inhibitor , ezetimibe , Cholestin™ [ red yeast rice ] red yeast product within 6 week , fibrates within 8 week randomization visit ( Visit 3 ) . Note : Fish oil , phytosterol margarine nonprescribed therapy allow provided participant stable dose 6 week prior Visit 2 agrees remain dose duration study . Is currently receive cyclical hormonal contraceptive intermittent use hormone replacement therapy ( HRTs ) ( e.g. , estradiol , medroxyprogesterone , progesterone ) . Note : Participants stable dose noncyclical HRT hormonal contraceptive great 6 week prior Visit 1 eligible agree remain regimen duration study . Is take prohibited medication systemic corticosteroid , potent inhibitor Cytochrome P450 3A4 ( CYP3A4 ) , cyclosporine , danazol , fusidic acid . Consumes &gt; 1 quart grapefruit juice/day . Requires warfarin treatment stable dose stable International Normalized Ratio ( INR ) least 6 week prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Low-density lipoprotein</keyword>
	<keyword>LDL</keyword>
	<keyword>High-density lipoprotein</keyword>
	<keyword>HDL</keyword>
	<keyword>Niacin</keyword>
	<keyword>Lipid modifying therapy</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>High cholesterol</keyword>
	<keyword>Triglycerides</keyword>
</DOC>